Category: Gastrointestinal
-
From gut resets to microbiome rejuvenation: DDW 2026 highlights transformative approaches to digestive health
An endoscopic procedure that maintains weight loss after stopping GLP-1 drugs, the double hit of stress and late-night eating on gut health, rising rectal cancer deaths in millennials, and youthful microbiome transplants that prevent liver cancer.
-
Regeneron and Tessera ink $275 mil pact for gene editing therapy
The companies will co-develop TSRA-196, a potential one-time genetic treatment for alpha-1 antitrypsin deficiency.
-
UEGW 2025: AbbVie bolsters IBD data for Rinvoq and Skyrizi
New data and lead investigators also reinforce the importance of treating beyond symptoms in Crohn’s disease and ulcerative colitis.
-
Cinclus Pharma stock shoots up following partnership with Zentiva
The deal, worth up to €220 million, will grant Zentiva commercialization rights to the former AstraZeneca acid reflux drug in Europe.
-
Shilpa wins SEC–CDSCO nod to market fatty liver drug in India
The expert committee recommended approving the company’s Nor Ursodeoxycholic Acid 500 mg tablets to treat non-alcoholic fatty liver disease (NAFLD).
Latest posts
-
Navigating the Risks and Rewards of Biomarker-Based Surrogates and Accelerated Approval
The risks and rewards of biomarker-based surrogates are crucial for optimizing clinical trial outcomes and guiding effective treatments.
-
ASH25: Gallop’s LYT-200 shows unprecedented survival in AML
The company’s execs talk about the striking efficacy and safety signals seen in Phase I data, the science behind the molecule, and their vision for transforming AML therapy.
-
Promis reports first human evidence of aβ oligomer reduction by pmn310
PMN310 demonstrates dose-dependent reduction of amyloid-beta oligomers in human CSF, marking a key milestone in Alzheimer’s treatment development.
-
Urologic Health secures $11 million for non-invasive bladder monitoring
Urologic Health raises $11million seed funding to advance a catheter-free bladder monitoring platform toward FDA clearance and US market entry.
-
Novo Nordisk’s denecimig cuts bleeding in hemophilia A regardless of inhibitors
Phase III trial shows once‑monthly and once‑weekly denecimig (Mim8) significantly reduces annualized bleeding rate versus standard care, with up to 95% of patients bleed‑free.